Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $37.7 million.

  • Ani Pharmaceuticals' Accumulated Expenses rose 72.10% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 72.10%. This contributed to the annual value of $37.7 million for FY2024, which is 58.60% up from last year.
  • Ani Pharmaceuticals' Accumulated Expenses amounted to $37.7 million in FY2024, which was up 58.60% from $23.8 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Accumulated Expenses high stood at $37.7 million for FY2024, and its period low was $6.4 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $23.8 million (2023), whereas its average is $23.9 million.
  • Data for Ani Pharmaceuticals' Accumulated Expenses shows a peak YoY skyrocketed of 130.66% (in 2023) over the last 5 years.
  • Ani Pharmaceuticals' Accumulated Expenses (Yearly) stood at $6.4 million in 2020, then spiked by 33.01% to $8.5 million in 2021, then rose by 21.00% to $10.3 million in 2022, then soared by 130.66% to $23.8 million in 2023, then soared by 58.60% to $37.7 million in 2024.